Alvotech (ALVO) Stock Analysis & Winston Score

Alvotech is a biopharmaceutical company that makes biosimilars — medicines that are nearly identical copies of expensive biological drugs. These products treat serious conditions like arthritis, inflammatory diseases, and eye disorders. The company sells its biosimilars to healthcare providers and partners with larger pharmaceutical distributors to reach patients, mainly in the United States and Europe. Alvotech earns money by selling its biosimilar products and through licensing and commercialization agreements with regional partners, which helps it reach markets without building its own sales force everywhere. Headquartered in Iceland, it operates manufacturing facilities focused entirely on biologics, which gives it a specialized production capability that is difficult and costly to replicate. The company's gross margin is strong, but its negative return on invested capital signals it is still spending heavily to build out its pipeline and pay down debt — successfully launching additional biosimilars and gaining market share against entrenched branded drugs remains the central challenge ahead.